Table_1_Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.DOCX
Background and Objective: Previous studies have evaluated the efficacy (OS, overall survival; PFS, progression-free survival; ORR, objective response rate) and adverse events of bevacizumab combined with platinum-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer (NSCLC) compared with chemotherapy alone. However, the results were inconsistent.
Methods: We conducted a comprehensive search of PubMed, EMBASE, and Cochrane Library for potentially eligible articles. The outcomes were evaluated in terms of risk ratio (RR) or hazard ratio (HR) and the associated 95% confidence intervals (CIs). Meta-analysis was performed using the Stata 12.0 software, and subgroup analyses were performed based on the treatment and bevacizumab dose.
Results: Six randomized controlled trials with 2,465 patients were included in this meta-analysis. The results demonstrated that bevacizumab significantly increased OS (HR = 0.87, 95% CI 0.79–0.96), extended PFS (HR = 0.65, 95% CI 0.54–0.77), and increased ORR (ES = 0.40, 95% CI 0.31–0.48) when added to first-line platinum-based chemotherapy in patients with advanced NSCLC. Subgroup analyses showed that only the higher dose (15 mg/kg) of bevacizumab plus carboplatin–paclitaxel significantly extended the OS and PFS, but both 7.5 mg/kg and 15 mg/kg of bevacizumab improved ORR. However, both 7.5 mg/kg and 15 mg/kg of bevacizumab could only increase PFS and ORR, but not extend OS, when added to cisplatin–gemcitabine. Bevacizumab significantly increased the risk of grade ≥3 events of febrile neutropenia, haemorrhagic events, hypertension, leukopenia, neutropenia, and proteinuria.
Conclusion: Bevacizumab significantly increases OS, PFS, and ORR when added to first-line platinum-based chemotherapy in patients with advanced NSCLC, with no new safety signals found. Moreover, bevacizumab (15 mg/kg) plus carboplatin–paclitaxel is a better alternative in increasing OS to carboplatin–paclitaxel and bevacizumab (7.5 mg/kg and 15 mg/kg) plus cisplatin–gemcitabine.
History
References
- https://doi.org//10.1093/annonc/mds590
- https://doi.org//10.1634/theoncologist.12-10-1183
- https://doi.org//10.1002/cncr.23063
- https://doi.org//10.1200/JCO.2008.19.4522
- https://doi.org//10.1093/annonc/mdy275
- https://doi.org//10.1038/nrd1381
- https://doi.org//10.1056/NEJMoa061884
- https://doi.org//10.1097/JTO.0b013e3181da36f4
- https://doi.org//10.1200/JCO.2014.59.4424
- https://doi.org//10.1200/JCO.2007.13.1144
- https://doi.org//10.1097/JTO.0b013e318265b500
- https://doi.org//10.1016/j.lungcan.2011.12.005
- https://doi.org//10.1200/JCO.2007.14.5466
- https://doi.org//10.2165/11532260-000000000-00000
- https://doi.org//10.1016/j.lungcan.2011.01.028
- https://doi.org//10.1093/annonc/mdq020
- https://doi.org//10.1016/j.jclinepi.2009.06.006
- https://doi.org//10.1097/MD.0000000000012666
- https://doi.org//10.1186/s12891-019-2972-7
- https://doi.org//10.1097/BRS.0000000000003193
- https://doi.org//10.1093/rheumatology/keaa644
- https://doi.org//10.1016/j.wneu.2018.10.115
- https://doi.org//10.1200/JCO.2004.11.022
- https://doi.org//10.1056/NEJMoa032691
- https://doi.org//10.1016/S1470-2045%2816%2930154-1
- https://doi.org//10.1200/JCO.2005.01.8234
- https://doi.org//10.1093/annonc/mdq204
- https://doi.org//10.1200/JCO.2008.16.2412
- https://doi.org//10.1097/JTO.0b013e3182370e02
Usage metrics
Read the peer-reviewed publication
Categories
- Radiology and Organ Imaging
- Foetal Development and Medicine
- Obstetrics and Gynaecology
- Primary Health Care
- Medical and Health Sciences not elsewhere classified
- Dermatology
- Emergency Medicine
- Gastroenterology and Hepatology
- Geriatrics and Gerontology
- Intensive Care
- Medical Genetics (excl. Cancer Genetics)
- Nephrology and Urology
- Nuclear Medicine
- Orthopaedics
- Otorhinolaryngology
- Pathology (excl. Oral Pathology)
- Family Care